Brazil has approved the use of the world’s first single-dose dengue vaccine. The vaccine, developed in Brazil, is authorized for people aged 12 to 59 who are at risk of dengue infection.
The vaccine underwent eight years of trials before approval, showing strong safety and effectiveness results. It was developed locally with assistance from a Chinese company and contains a live dengue virus, similar to how polio vaccines use live virus.
Read more: Dengue Cases Rise as Lahore Reports Three Deaths
Trials showed the vaccine reduces overall dengue fever symptoms by 74%. Severe dengue symptoms dropped by 84% after vaccination, indicating high protection against serious illness.
The vaccine is currently authorized only for adults and young adults aged 12–59. Plans are underway to expand its use for younger children and older adults in the near future.
Read more: ICT reports six new dengue cases in 24 hours
Initially, the vaccine will be used only in Brazil. In later stages, it may be distributed to other countries. Previously, the World Health Organization had approved only a two-dose dengue vaccine requiring a three-month gap between doses.